Vermont Tech Scene
SEE OTHER BRANDS

Exploring the science and technology news of Vermont

Vermont Tech Scene: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.

Press releases published on May 6, 2025

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has …

Netcoins Canada Provides Q1 2025 Results

Netcoins Canada Provides Q1 2025 Results

VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BIGG Digital Assets Inc. (“BIGG” or the “Company”) (TSXV: BIGG; OTCQX: BBKCF; WKN: A2PS9W), a leading innovator in the digital assets space and owner of Netcoins, Blockchain Intelligence Group, …

Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion

Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion

Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May 06, 2025 ( …

Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results and Business Highlights

Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results and Business Highlights

— First quarter revenue of $16.7M, +26% year-over-year growth; IFRS gross margin of 76.3% — First quarter pulse recurring revenue of $7.0M, +49% year-over-year growth — IFRS and non-IFRS operating loss of -$1M and -$0.2M, respectively SAN CLEMENTE, Calif., …

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development …

UMeWorld Releases Clinical Results: DAG Oil Shows Significant Reductions in Uric Acid, Cholesterol, Triglycerides, and Weight

UMeWorld Releases Clinical Results: DAG Oil Shows Significant Reductions in Uric Acid, Cholesterol, Triglycerides, and Weight

MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) today announced the results of a clinical study demonstrating the metabolic benefits of diacylglycerol (DAG) oil, the active ingredient in its functional cooking oil brand, DAGola. The …

Orangekloud to Attend Directions ASIA 2025 Conference, May 7-9, in Bangkok

Orangekloud to Attend Directions ASIA 2025 Conference, May 7-9, in Bangkok

SINGAPORE, May 06, 2025 (GLOBE NEWSWIRE) -- Orangekloud Technology Inc. (Nasdaq: ORKT) (“Orangekloud” or “the Company”), a pioneer in AI-driven no-code application development, today announced that the Company will be attending the Directions ASIA 2025 …

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

WARRINGTON, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …

Atsign Supercharges File Sharing with Invisible SMB/CIFS Connections

Atsign Supercharges File Sharing with Invisible SMB/CIFS Connections

SAN JOSE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Atsign, the leader in invisible zero trust connectivity solutions, today announced that its NoPorts technology now supports invisible SMB/CIFS connections. This breakthrough enables users to access file …

Plotly Showcases AI-powered Platform for Interactive Data Application Development at Leading Industry Events in May and June 2025

Plotly Showcases AI-powered Platform for Interactive Data Application Development at Leading Industry Events in May and June 2025

MONTREAL, May 06, 2025 (GLOBE NEWSWIRE) -- Plotly, the premier Data App platform for Python, today announced it will participate in multiple leading industry events in May and June, 2025, where Plotly experts and users will share their unique insights and …

FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY REACHES KEY OPERATIONAL MILESTONES

FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY REACHES KEY OPERATIONAL MILESTONES

WEST PALM BEACH, FLORIDA, May 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has reached key patient care milestones. …

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its …

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics to Present at Upcoming Investor Conferences

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, …

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …

Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy

Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy

Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).[1 …

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical …

ReportAId raises €2.2M using AI to unlock healthcare data

ReportAId raises €2.2M using AI to unlock healthcare data

Milan, May 06, 2025 (GLOBE NEWSWIRE) -- Ask any doctor what's keeping them from delivering better care, and paperwork will top the list. Despite billions invested in healthcare technology, 80% of clinical data remains trapped in unstructured reports, and …

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David …

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

-- Data will be featured at EULAR Annual Congress – BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service